Peptide
Humanin
Humanin (24-amino-acid mitochondrial-derived peptide)
A mitochondrial-derived peptide that falls with age and correlates with insulin sensitivity and neuroprotection. The HNG analog is roughly 1000 times more potent than native humanin but has no completed human RCT.
Summary Could humanin slow aging or improve health? Show / hide ↓
Humanin is a small substance made by mitochondria, the parts of cells that produce energy. Its blood levels often fall with age and are linked to better insulin sensitivity, meaning the body responds better to insulin, and protection of nerve cells. A modified form called HNG improved blood sugar control and memory in animal studies at 0.25 to 0.5 milligrams per kilogram, but this does not show the same effects in people. No completed human randomized controlled trial, a study that compares treatments fairly, has tested humanin or HNG. Human use has included 0.25 to 0.5 milligrams by injection two or three times weekly, but the benefits and risks at these doses are unknown and low blood sugar is a concern.
What this means for you: Humanin is an interesting but unproven longevity treatment. The animal findings and age-related links are not enough to recommend buying or using it, especially because human safety and effectiveness remain unknown.
early evidenceHumanin was the first mitochondrial-derived peptide identified in humans, isolated by Yuichi Hashimoto's group in Tokyo in 2001 from a brain region relatively preserved in Alzheimer's disease. The initial claim, later replicated by multiple groups, was that humanin binds and neutralizes Bax at the mitochondrial outer membrane, preventing apoptosis in cultured neurons exposed to amyloid-beta.
The biology has expanded since. Humanin circulates in human blood, falls markedly with age (roughly 50 percent lower in 70-year-olds versus 20-year-olds in some cohorts), and correlates inversely with insulin resistance, metabolic syndrome markers, and Alzheimer risk. Centenarians and their offspring have higher circulating humanin than age-matched controls in the Longevity Genes Project cohort. This is correlational, not causal, but the pattern is unusually clean.
Mechanistically, humanin signals through the CNTFR/WSX-1/gp130 receptor complex in some tissues and directly through mitochondrial binding partners in others. Downstream effects include AMPK activation, improved glucose uptake in muscle, and reduced apoptosis in neurons and pancreatic beta cells.
The HNG analog was engineered to solve humanin's short half-life and low potency. In animal models of type 2 diabetes and Alzheimer's, HNG at doses of 0.25 to 0.5 mg per kg produces measurable improvements in insulin sensitivity and cognitive endpoints. No completed human RCT of native humanin or HNG has reached the literature as of 2026.
Inside the biohacking community, HNG or synthetic humanin is used at 0.25 to 0.5 mg subcutaneous, two to three times per week, in the morning to avoid interaction with fasted-state metabolism. The insulin-sensitizing effect creates a real hypoglycemia risk in users who combine humanin with fasting or with glucose-lowering supplements. This is not a theoretical caution; users have reported symptomatic hypoglycemia at these doses.
Our position: Humanin sits at Tier 4. The endogenous origin, the aging correlations, and the mechanism are unusually strong. The absence of a completed human RCT is the gap. HNG is potent enough that a real trial would produce a clear signal quickly, and the fact that no pharmaceutical program has run one is itself informative.
Further reading
Curated external sources for a deeper dive. External links open in a new tab.